Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Vaxcyte, Inc.NASDAQ: PCVX

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow growth accelerates

Q2 FY2026 free cash flow of $532.46M (cash outflow) rose 423.8% year over year, ahead of the +124.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 80.2% from the prior quarter. Over 3 fiscal years it compounded at +56.0% a year.

Context

  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +423.8% holds above the trailing-twelve-month pace of +124.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$532.46M+80.2% QoQ
Last fiscal yearDec 2025
-$669.29M+40.9% YoY
LTMJun 2026
-$1.2B+124.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+423.8%——
1 year+40.9%——
3-year CAGR+56.0%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(669.29M) USD
Year-over-year change
-40.9%

Free Cash Flow vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +124.8% is the highest of 9, against a peer median of -10.1%.
  • Over three fiscal years its annual growth of +56.0% compares with a peer median of -21.1%.
PCVX Competitors
Free Cash Flow for PCVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$10.99B USD-11.7%-29.6%17.2%
GSKGSK plcLTM Jun 2026£6.98B GBP+49.6%-4.8%21.0%
MRNAModerna, Inc.LTM Sep 2026$1.95B USD-26.8%—77.2%
PCVXVaxcyte, Inc.LTM Jun 2026$1.2B USD+124.8%+56.0%—
VIRVir Biotechnology, Inc.LTM Mar 2026$444.81M USD+5.4%—679.2%
IBRXImmunityBio, Inc.LTM Sep 2026$297.09M USD-8.5%-9.4%162.7%
NVAXNovavax, Inc.LTM Mar 2026$97.17M USD-51.0%-21.1%16.3%
VALNValneva SELTM Mar 2026€70.92M EUR+4.6%-40.7%45.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$58.89M USD-34.5%—129.9%
Peer median (excluding PCVX) —-10.1%-21.1%61.3%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
Deferred Income Tax00000
Stock-Based Compensation10.73M23.65M48.76M84.82M138.85M
Change in Working Capital(37.01M)12.74M81.32M(54.9M)(3.45M)
Accounts Receivables00000
Inventory00000
Accounts Payables(12.47M)2.9M11.23M34.58M19.91M
Other Working Capital(24.54M)9.84M70.1M(89.48M)(23.36M)
Other Non-Cash Items1.5M7.05M(34.78M)(34.47M)(49.2M)
Operating Cash Flow(121.39M)(170.6M)(296.79M)(452.63M)(655.58M)
Capital Expenditures(6.56M)(5.84M)(67.88M)(22.43M)(13.71M)
Acquisitions (Net)00000
Purchases of Investments(336.34M)(102.75M)(1.33B)(3.09B)(1.21B)
Sales of Investments130.56M183.17M624.46M1.2B1.71B
Other Investing Activities26K00(96.73M)(43.26M)
Investing Cash Flow(212.31M)74.59M(773.31M)(2.01B)437.35M
Debt Repayment00000
Common Stock Issued13.9M856.48M636.04M2.44B13.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.9M5.07M3.77M12.85M(10.99M)
Financing Cash Flow17.8M861.55M639.81M2.45B2.01M
Effect of Forex Changes(439K)137K(6.69M)426K2.44M
Net Change in Cash(316.34M)765.67M(436.97M)(9.36M)(213.77M)
Free Cash Flow(127.95M)(176.44M)(364.67M)(475.05M)(669.29M)

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.